# A Phase II Study of CRT Combined With QL1706 in ESCC Patients

> **NCT05490719** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** QL1706

## Key facts

- **NCT ID:** NCT05490719
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-09
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490719, "A Phase II Study of CRT Combined With QL1706 in ESCC Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05490719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*